Wegovy’s success triggered a pharma gold rush, forecasting a potential industry’s biggest-ever blockbuster treatments.
Novo has vaulted into the limelight as Wegovy and another related medicine for diabetes, Ozempic, proved they could help people shed unwanted weight by curbing their appetite. For now, it’s restricting starter doses for Wegovy — which can help overweight people lose about 15% of their body weight — to safeguard supplies for people in the US who are already on the medicine, the company said.
“Overall a strong set of numbers from Novo Nordisk – driven by Wegovy,” Brian Godsk Borsting, a credit analyst at Danske Bank A/S, said in a note.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: